Loading...
Loading...
In a report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Gilead Sciences
GILD, and raised the price target from $48.00 to $69.00.
In the report, Karnauskas noted, “We built a monthly HCV market model and analyzed prior treatment trends to derive our estimates for 14,15-16, and 17+ as GILD plans to provide some color YE on these markets. Our conclusion is that SOF can sell WW $3.7B, $8.4B, $12.4B in 14, 15, and peak respectively. We analyzed the co's new HIV drug TAF and now include its impact in our model. Maintain Buy.”
Gilead Sciences closed on Monday at $50.67.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in